Madrigal Pharmaceuticals, Inc. develops and commercializes therapies for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease that can progress to cirrhosis and liver failure. Its principal medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist approved by the FDA and European Commission for MASH with moderate to advanced fibrosis.
Company news regularly covers Rezdiffra sales and patient adoption, quarterly financial results, regulatory and clinical development updates, and pipeline expansion through licensed assets such as ARO-PNPLA3, a clinical-stage siRNA program targeting PNPLA3, and an oral GLP-1 receptor agonist program. Madrigal also issues recurring corporate-governance updates, including Nasdaq inducement awards under its employee equity plans.
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported robust financial results for 2022, highlighting a year-end cash position of $358.8 million, up from $270.3 million in 2021. The company is advancing regulatory preparations for resmetirom, following positive Phase 3 MAESTRO-NASH study results, which demonstrated both NASH resolution and fibrosis improvement. These results support a New Drug Application (NDA) filing projected for the first half of 2023. Operating expenses rose to $293.6 million for the year, attributed to increased clinical trial activities and commercial preparations.
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical firm, targets therapies for nonalcoholic steatohepatitis (NASH). The company's management will present at three key investor conferences: the SVB Securities Global Biopharma Conference on February 14, Cowen Annual Healthcare Conference on March 6, and the Oppenheimer Annual Healthcare Conference on March 13, 2023. Each presentation will be available via webcast, and recordings will be archived on Madrigal’s website. Madrigal’s lead candidate, resmetirom, is designed to address significant unmet needs in NASH.
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported promising results from the Phase 3 MAESTRO-NASH trial of resmetirom, targeting NASH and liver fibrosis. The study demonstrated significant improvements in primary endpoints, including NASH resolution and fibrosis reduction. These results, validated by consensus reads of biopsy images, will be presented at the NASH-TAG Conference. The company plans to submit a new drug application for resmetirom seeking accelerated approval in 2023, supported by extensive safety and efficacy data from ongoing trials, bolstering its potential market impact in treating NASH.
Madrigal Pharmaceuticals (NASDAQ: MDGL) announced raising $259 million in equity and $50 million in additional debt financing following a positive topline readout from its Phase 3 MAESTRO-NASH trial. This funding will support commercial and clinical activities, including a planned new drug application for resmetirom in the first half of 2023. The company's recent capital raises include $159 million in ATM Program sales and a $100 million securities purchase agreement with institutional investors, confirming strong backing from long-standing investors.
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced positive topline results from its Phase 3 MAESTRO-NASH trial for resmetirom, targeting nonalcoholic steatohepatitis (NASH) with liver fibrosis. The trial demonstrated significant efficacy, achieving primary endpoints with p-values 0.0001. Key outcomes included NASH resolution in 26% and 30% of patients at 80 mg and 100 mg doses, respectively, alongside a substantial LDL reduction. Resmetirom was deemed safe and well-tolerated. Madrigal plans to file for accelerated approval with the FDA in early 2023.
Madrigal Pharmaceuticals (NASDAQ: MDGL) is set to announce topline results from its Phase 3 MAESTRO-NASH study of resmetirom on December 19, 2022. The press release will be available at 7:00 am EST, followed by a conference call at 8:00 am EST. Resmetirom is an innovative oral therapy targeting nonalcoholic steatohepatitis (NASH), an area of high unmet medical need. Madrigal aims to address the underlying causes of NASH through its thyroid hormone receptor-selective approach.
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced it will present two oral abstracts at the AASLD Liver Meeting, showcasing promising Phase 3 data for resmetirom, a potential treatment for compensated NASH cirrhosis. The MAESTRO-NAFLD-1 study indicates significant reductions in cardiovascular risk markers and NASH fibrosis after 52 weeks of resmetirom treatment. Financially, the company reported $153.2 million in cash and equivalents, a decrease from $270.3 million at year-end 2021, fueled by operational expenses of $166.3 million. Upcoming topline data from the MAESTRO-NASH study is expected in Q4 2022.
Madrigal Pharmaceuticals (NASDAQ: MDGL) announced that its management team will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 9:30 AM ET. The event will be webcasted, with an archived recording available on the company's website. Madrigal focuses on novel therapeutics for nonalcoholic steatohepatitis (NASH), with its leading candidate, resmetirom, currently undergoing four Phase 3 clinical studies aimed at addressing this significant liver disease.
Madrigal Pharmaceuticals (NASDAQ:MDGL) has initiated the "MAESTRO-NASH Outcomes" study for resmetirom, targeting NASH cirrhosis progression. This Phase 3, double-blind trial will enroll about 700 patients and measure composite liver-related outcomes over 2-3 years. Positive results could support full approval for resmetirom in both noncirrhotic and cirrhotic NASH populations. The study is the fourth in the MAESTRO series, building on previous promising data from earlier trials. Completion and results of this study are crucial for the company’s future prospects.
Madrigal Pharmaceuticals (MDGL) shared updates on its progress and reported Q2 2022 financial results. The company is advancing its Phase 3 MAESTRO-NASH biopsy study, with topline data expected in Q4 2022. Resmetirom, an oral medication targeting NASH, shows promise, supported by positive safety data. As of June 30, 2022, Madrigal reported $211.8 million in cash and equivalents, down from $270.3 million at year-end 2021, driven by operational cash use of $107.3 million. Operating expenses rose to $70.3 million, attributed to increased research activities and headcount.